Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Smoking
Interventions: Not listed
Lead sponsor: Avioq, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Spinal Cord Injury, Neurogenic Bladder (NB), Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Spina Bifida, Urinary Tract Infection(UTI)
Interventions: Gentamicin, Lactobacillus Rhamnosus GG; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Pittsburgh, Pennsylvania

Conditions: Diurnal Residual Limb Fluid Volume Fluctuation
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Tobacco-Related Carcinoma
Interventions: Vaping, Biospecimen Collection, Questionnaire Administration; Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Neoplasms
Interventions: Dexamethasone, Trabectedin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 21
States / cities: Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more

Conditions: Osteopathic Manipulative Treatment (OMT) Effects on Cerebrospinal Fluid (CSF) Dynamics
Interventions: Osteopathic Manipulative Treatment (OMT); Other
Lead sponsor: Edward Via Virginia College of Osteopathic Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Melanoma
Interventions: Intetumumab, Dacarbazine, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more

Conditions: Anxiety, Depressive Symptoms
Interventions: Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 13 Years to 24 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acne Vulgaris
Interventions: Winlevi (Clascoterone) cream 1%; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Acute Decompensated Heart Failure
Interventions: Reprieve Decongestion Management System, Diuretic; Device · Drug
Lead sponsor: Reprieve Cardiovascular, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 16
States / cities: Fairhope, Alabama • Irvine, California • Washington D.C., District of Columbia + 12 more

Conditions: Congestive Heart Failure
Interventions: PsychoEducational Support, Usual Care; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post-Operative Ileus (POI)
Interventions: Methylnaltrexone, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Blood Draw, CSF collection by lumbar puncture (Optional); Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Lymphoma
Interventions: Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid), Rituximab, Polatuzumab vedotin (Lyophilized); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Huntsville, Alabama • Duarte, California + 13 more

Conditions: Breast Cancer
Interventions: Definity infusion; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Decompensated Heart Failure
Interventions: Furosemide Injection Solution 8mg/mL; Drug
Lead sponsor: Todd M Koelling, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pancreatic Cysts
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Pancreatic Cancer
Interventions: high performance liquid chromatography, pharmacological study, [18F]-labeled substance P antagonist receptor quantifier; Other · Radiation
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Down Syndrome
Interventions: Donepezil HCl, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 31
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Cystic Fibrosis
Interventions: Alpha-1 HC 100 mg, Placebo, Alpha-1 HC 200 mg; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Fluid Output
Interventions: Electronic Device for Toilet; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Uveitis, Infectious Disease
Interventions: Metagenomic Deep Sequencing (MDS), Standard of Care (SOC); Device · Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: SARS-CoV-2
Interventions: mRNA-1283, mRNA-1283.211, mRNA-1273, mRNA-1283.529; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Phoenix, Arizona • Hollywood, Florida • Sunrise, Florida + 13 more

Conditions: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Colesevelam; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Evaluation of An Oral Fluid Collection Device

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD

Accommodating for Residual Limb Fluid Volume Change

Effects of Tobacco Flavoring and Liquid Composition on Vaping Topography

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

Exploring How Osteopathic Manipulative Treatment May Affect Spinal Fluid Flow: An MRI Study

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

A Single-Session Intervention for Adolescents and Young Adults With Internalizing Problems

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

Project Fluido: Fluid Watchers

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy

A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen

Registry and Fluid Banking of Pancreatic Cystic Lesions

Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Testing a Device for Automatically TRacking Urine and STool in an Inpatient HCT Setting (Project TRUST)

Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids